AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 38 |
Market Cap | 2.67B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -3.72 |
PE Ratio (ttm) | -10.48 |
Forward PE | n/a |
Analyst | Buy |
Ask | 40.67 |
Volume | 1,008,817 |
Avg. Volume (20D) | 560,991 |
Open | 40.62 |
Previous Close | 40.45 |
Day's Range | 38.63 - 40.62 |
52-Week Range | 31.27 - 61.61 |
Beta | undefined |
About MRUS
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also de...
Analyst Forecast
According to 11 analyst ratings, the average rating for MRUS stock is "Buy." The 12-month stock price forecast is $85, which is an increase of 117.95% from the latest price.
Next Earnings Release
Analysts project revenue of $8.95M, reflecting a 0.12% YoY growth and earnings per share of -0.94, making a -13.76% decrease YoY.